Market Review: June 17, 2026

Closing Recap

Wednesday, June 17, 2026

In a surprise “hawkish” shift for rate policy, U.S. stock markets pulled back off intraday highs as stock markets now fully price a 25bp Fed rate hike before year-end following the FOMC new rate projections. Markets took the news that 50% of FOMC members (9 of 18) penciling in one rate hike minimum for 2026 as Iran-war price shock crushes consumers as a hawkish surprise. The updated policy statement removed language that had been used to flag the likelihood of further reductions in borrowing costs this year. New projections show inflation slowing sharply next year, allowing rates to return to where they are now by the end of 2027 and easing modestly further in 2028. Treasury yields and the US dollar soared after the release of the policy statement and projections, weighing on sentiment, while precious metals reversed lower. The Dow Jones Industrial Average snapped its winning streak for the week, pulling back off all time highs.

Kevin Warsh’s 1st press conference begins with 3 big messages: 1) Inflation: “This committee will deliver price stability” 2) No forward guidance. “We agreed [it] was not well suited for the current policy juncture.” Dot Plot will continue, but Warsh won’t participate; 3) Warsh launching 5 task forces to “propose next steps” for policymaker consideration, including on Fed communication. Warsh says the Fed has given markets “a new chapter for the central bank,” and acknowledges “this is a lot of change for financial markets to digest.” Says he won’t be particularly intrigued by how markets react in the first minutes or days, but markets and the public “must know Fed will deliver on price stability.” Adds the Fed needs to make sure price changes in oil, eggs, beef, and the like don’t broaden across the economy.

Stock markets dipped notably after the rate projections were released at 2:00 pm et which showed greater chances of rate hikes this year, which sunk bonds (boosting yields), as well as sectors leveraged to rates such as Smallcaps and homebuilders, etc. As new Fed Chairman Warsh spoke, markets regained solid footing as the big dip in semis and AI names after the 2:00 announcement were bought aggressively, lifting broader markets despite a sharp decline in large cap tech today (META, MSFT, GOOGL, AMZN). Sharp declines in Consumer Staples (XLP), REITs (XLRE), Communications (XLC) and Healthcare (XLV). Lots of volatility as the first meeting with Warsh as chair had a little something for everyone.

In a quick synopsis of the Fed meeting/presser: They held rates at 3.50%-3.75%, but the real story was the shift in tone as their easing bias was removed, the 2026 dot plot moved higher, while core PCE inflation forecast raised to 3.3% and policymakers now see a hike as more likely than a cut…and still, markets were down only slightly just off record highs for major averages. Other items to watch this week include quad witching as a $5.15 trillion worth of options on the S&P 500 are set to expire on June 19th, the largest monthly expiration on record. This is led by the S&P 500 index options, which account for $4.84 trillion of the total. The remaining $307 billion consists of options on the S&P 500 ETF.

• April Business Inventories +0.5% while U.S. April inventory/sales ratio 1.31 months’ worth vs March 1.32 months; U.S. April business sales +1.2% vs March +2.2% (prev +2.1%).
• May pending home sales: +3.8% M/M vs. +0.9% consensus and +0.3% prior (revised from +1.4%), according to data released by the National Association of Realtors.

• Fed officials’ median view of Fed funds rate at end-2026 3.8% (prev 3.4%), Fed officials’ median view of Fed funds rate at end-2027 3.6% (prev 3.1%), Fed officials’ median view of Fed funds rate at end-2028 3.4% (prev 3.1%) and Fed officials’ median view of Fed funds rate in longer run 3.1% (prev 3.1 %).
• Fed projections imply 25 basis points of rate hikes in 2026, followed by 25 bps of rate cuts in 2027 and another 25 bps of cuts in 2028. Fed projections show PCE inflation not expected to return to 2.0% target until 2028, unchanged from March projection. Fed policymakers see 4.3% unemployment rate at end of 2026 versus 4.4% in March projections. Fed policymakers see end-2026 PCE inflation at 3.6% versus 2.7% in March; core seen at 3.3% versus 2.7%. Fed policymakers see 2.2% GDP growth in 2026 versus 2.4% in March, see longer-run growth at 2.0% vs 2.0% in March

• U.S. crude oil futures settle at $76.79/bbl, up 74 cents, or 0.97%, snapping a string of several declines while Brent crude futures settle at $79.55/bbl, up 59 cents, or 0.75%. August gold rises +$27.00 or +0.62%, to settle at $4,381.40 but spot gold prices fell sharply after the Fed signals potential rate hikes ahead. July silver gained +$0.75/oz, or +1.08%, at $70.77 an ounce, but also reversed lower following the FOMC.

• Housing: CVCO and SKY shares were strong early after last night Senate leaders reached a final deal on a revised version of the comprehensive housing legislation, which includes multiple provisions to boost manufactured housing. The Senate then took a key procedural step forward. Both co’s are seen as pure-play manufactured/modular housing producers and stand to benefit from these reforms.

• Auto retail: sector was weak as KMX shares slide following results; Q1 revs rose 6% Y/y to $8B vs. est. $7.41B; Q1 EPS fell -5.1% Y/y to $1.31; Q1 Gross profit declined 4.4% Y/y due to lower retail unit margins from pricing actions; shares of CVNA declined in sympathy.

• Gas sector: shares of LNG, VG were weak Tuesday after Qatar is beginning to bring its LNG tankers back to the Middle East as it prepares to ramp-up exports. At least 5 empty Qatar-linked tankers linked are returning after being idle. 4 more ships in Gulf of Oman. Qatar hasn’t sent an empty LNG ship through Hormuz in 3+ months.
• In Chemicals: FMC entered a co-exclusive supply and license agreement with CTVA for rimisoxafen herbicide technology in North and South American corn, soybean markets. Corteva will make an initial prepurchase payment of $200M for product supplied by FMC.

• Exchanges: CME shares fell after Terry Duffy will step down as Chief Executive Officer and transition to executive Chairman of the board in March 2027; President and CFO Lynne Fitzpatrick will be appointed CEO. CBOE fell for a 5th straight day and falling further below its 200dma support around $274 as exchanges along with CME remain pressured on the perceived competitive risk of perpetual futures.
• Digital platforms: FIG shares bounced, snapping an 11 day losing streak after Citigroup initiated at Buy and $36 tgt as  believes the company’s ramping AI traction will dive significant upside to consensus estimates.
• Insurance: PGR May net premiums earned $7.36 billion, up 10% and May net premiums written $7.03 billion, up 6%; May combined ratio improves to 82.1 from 86.9; total pretax net realized gains on securities $215 million.

• JAZZ and ABCL announce collaboration to discover next-generation T-cell engaging Mult specific antibodies; the collaboration includes $56M upfront and up to $792M option fees per program; Jazz has exclusive option to develop and commercialize antibodies from collaboration.
• QURE shares jump after saying it plans to apply for regulatory approval to market one of its primary investigational gene therapies as a treatment for Huntington’s disease; said the FDA told the company that a three-year analysis from a study of UniQure’s AMT-130 drug would be acceptable as the primary basis for a Biologics License Application to accelerate approval of the drug.
• Shares of CLPT, REPL, BHVN, PTCT, NTLA, CAPR, SRPT several Biotech/rare-disease and Neuro/gene therapy stocks are rising with QURE’s news today with the FDA accepting 3-year Phase 1/2 data for accelerated BLA submission in HD, reversing earlier setbacks – signals a potentially favorable FDA stance on innovative Therapies for rare/neurodegenerative diseases.
• VSTM announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a; Recommended Phase 2 Dose cohort of 29 patients evaluating avutometinib plus defactinib in combination w/gemcitabine and nab-paclitaxel in first-line metastatic pancreatic adenocarcinoma.
• SPRO shares fell as partner GSK said the FDA approved oral antibiotic to treat complicated urinary tract infections. The approval makes GSK’s drug the first oral carbapenem, a class of antibiotics which are widely used for the treatment of drug-resistant gram-negative bacterial infections.

• Medical Equipment: RMD was downgraded from Overweight to Equal Weight at Morgan Stanley and cut tgt to $230 from $286 noting recent commentary from key component suppliers highlights pricing increases, with FX movements likely to present incremental near-term headwinds. The firm sees price increases and further operational efficiencies as potential offsets.

• LDOS was downgraded to Neutral from Buy at Bank America and lowered tgt to $125 from $200 as they now see downward pressure in the near term for their healthcare unit as the Defense Health Agency works on trying to work directly with suppliers in the Defense Healthcare Management System Modernization maintenance phase

• Semiconductors (SOX) looked to rebound with shares higher after the SOX fell 5% off all-time highs reached on Monday with early gains for INTC, NVDA, MU and MRVL among others, though the standouts in the sector are equipment stocks with AMAT, LRCX, KLAC, ASML, TER all jumping.
• AEHR received a follow-on production order for a fully automated Fox-XP wafer-level burn-in system from a major silicon Photonics customer. System is configured to test nine wafers in parallel, including an Integrated WaferPak Auto Aligner and a set of Fox WaferPak Contactors
• AMD price tgt raised to $600 from $525 at Bernstein as the firm continues to see AMD as a key beneficiary of AI and data center demand.
• MU price tgt raised to $1,200 from $840 at Citigroup, reflecting increased confidence in Micron’s AI and memory market outlook as the firm continues to view Micron as a key beneficiary of rising AI-driven demand for memory products.